Jaquelina S Ota-Arakaki

List of Publications by Year
in descending order

54 papers	748 citations	566801 15 h-index	552369 26 g-index
54 all docs	54 docs citations	54 times ranked	988 citing authors

#	Article	IF	Citations
1	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 573-584.	5.2	85
2	Heart rate recovery in pulmonary arterial hypertension: Relationship with exercise capacity and prognosis. American Heart Journal, 2012, 163, 580-588.	1.2	67
3	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Research, 2021, 7, 00850-2020.	1.1	65
4	A haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis. European Respiratory Journal, 2014, 44, 415-424.	3.1	60
5	Detected SARS-CoV-2 in Ascitic Fluid Followed by Cryptococcemia: a Case Report. SN Comprehensive Clinical Medicine, 2020, 2, 2414-2418.	0.3	35
6	Optimizing the evaluation of excess exercise ventilation for prognosis assessment in pulmonary arterial hypertension. European Journal of Preventive Cardiology, 2014, 21, 1409-1419.	0.8	34
7	Diagnostic and prognostic value of right ventricular strain in patients with pulmonary arterial hypertension and relatively preserved functional capacity studied with echocardiography and magnetic resonance. International Journal of Cardiovascular Imaging, 2017, 33, 39-46.	0.7	33
8	Destaques das diretrizes de doenÃ§as pulmonares intersticiais da Sociedade Brasileira de Pneumologia e Tisiologia. Jornal Brasileiro De Pneumologia, 2012, 38, 282-291.	0.4	30
9	Usefulness of pulmonary capillary wedge pressure as a correlate of left ventricular filling pressures in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2014, 33, 157-162.	0.3	30
10	Kinetics of skeletal muscle O2 delivery and utilization at the onset of heavy-intensity exercise in pulmonary arterial hypertension. European Journal of Applied Physiology, 2011, 111, 1851-1861.	1.2	28
11	Nailfold capillaroscopy as a risk factor for pulmonary arterial hypertension in systemic lupus erythematosus patients. Advances in Rheumatology, 2019, 59, 1.	0.8	28
12	Exercise Intolerance in Pulmonary Arterial Hypertension. The Role of Cardiopulmonary Exercise Testing. Annals of the American Thoracic Society, 2015, 12, 604-612.	1.5	27
13	Schistosomiasis Pulmonary Arterial Hypertension. Frontiers in Immunology, 2020, 11, 608883.	2.2	22
14	Exercise oxygen uptake efficiency slope independently predicts poor outcome in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 1510-1512.	3.1	20
15	Hiperplasia de cÃ©lulas neuroendÃ³crinas pulmonares difusas com obstruÃ§Ã£o ao fluxo aÃ©reo. Jornal Brasileiro De Pneumologia, 2009, 35, 489-494.	0.4	16
16	Signalâ€morphology impedance cardiography during incremental cardiopulmonary exercise testing in pulmonary arterial hypertension. Clinical Physiology and Functional Imaging, 2012, 32, 343-352.	0.5	16
17	Uncovering the mechanisms of exertional dyspnoea in combined pulmonary fibrosis and emphysema. European Respiratory Journal, 2020, 55, 1901319.	3.1	16
18	Cerebral microvascular blood flow and CO 2 reactivity in pulmonary arterial hypertension. Respiratory Physiology and Neurobiology, 2016, 233, 60-65.	0.7	15

#	Article	IF	Citations
19	Carotid chemoreflex activity restrains postâ€exercise cardiac autonomic control in healthy humans and in patients with pulmonary arterial hypertension. Journal of Physiology, 2019, 597, 1347-1360.	1.3	12
20	Does oxygen pulse trajectory during incremental exercise discriminate impaired oxygen delivery from poor muscle oxygen utilisation?. ERJ Open Research, 2019, 5, 00108-2018.	1.1	10
21	Prevalence of sexual dysfunction in women with pulmonary hypertension and associated factors. Heart and Lung: Journal of Acute and Critical Care, 2021, 50, 714-719.	0.8	10
22	Contrasting Cardiopulmonary Responses to Incremental Exercise in Patients with Schistosomiasis-Associated and Idiopathic Pulmonary Arterial Hypertension with Similar Resting Hemodynamic Impairment. PLoS ONE, 2014, 9, e87699.	1.1	10
23	Ocular toxicity assessment of chronic sildenafil therapy for pulmonary arterial hypertension. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1167-1174.	1.0	8
24	Pulmonary haemodynamics and mortality in chronic hypersensitivity pneumonitis. European Respiratory Journal, 2018, 51, 1800430.	3.1	8
25	Inspiratory muscle weakness contributes to exertional dyspnea in chronic thromboembolic pulmonary hypertension. PLoS ONE, 2018, 13, e0204072.	1.1	8
26	Clinical utility of ventilatory and gas exchange evaluation during lowâ€intensity exercise for risk stratification and prognostication in pulmonary arterial hypertension. Respirology, 2021, 26, 264-272.	1.3	7
27	Insights into ventilationâ€“gas exchange coupling in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2016, 48, 252-254.	3.1	6
28	Cardiac baroreflex dysfunction in patients with pulmonary arterial hypertension at rest and during orthostatic stress: role of the peripheral chemoreflex. Journal of Applied Physiology, 2021, 131, 794-807.	1.2	5
29	Incremental step test in patients with pulmonary hypertension. Respiratory Physiology and Neurobiology, 2020, 271, 103307.	0.7	4
30	Thrombosis and anticoagulation in COVID-19. Jornal Brasileiro De Pneumologia, 2020, 46, e20200317-e20200317.	0.4	4
31	The clinical course of hospitalized moderately ill COVID-19 patients is mirrored by routine hematologic tests and influenced by renal transplantation. PLoS ONE, 2021, 16, e0258987.	1.1	4
32	Pulmonary artery wedge pressure and exercise oscillatory ventilation in pre-capillary pulmonary hypertension. International Journal of Cardiology, 2016, 206, 164-166.	0.8	3
33	Prognostic value of sixâ€minute walk distance at a South American pulmonary hypertension referral center. Pulmonary Circulation, 2020, 10, 1-6.	0.8	3
34	Arterial vascular volume changes with haemodynamics in schistosomiasis-associated pulmonary arterial hypertension. European Respiratory Journal, 2021, 57, 2003914.	3.1	3
35	Value of Contrast Transesophageal Echocardiography in the Detection of Intrapulmonary Vascular Dilatations in Hepatosplenic Schistosomiasis. Arquivos Brasileiros De Cardiologia, 2019, 113, 915-922.	0.3	3
36	Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. Jornal Brasileiro De Pneumologia, 2020, 46, e20200204-e20200204.	0.4	3

#	Article	IF	Citations
37	Impact of right ventricular work and pulmonary arterial compliance on peak exercise oxygen uptake in idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2021, 331, 230-235.	0.8	2
38	World Pulmonary Hypertension Day: reflections and planning. Jornal Brasileiro De Pneumologia, 2021, 47, e20210251.	0.4	2
39	Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study. , 2020, , .		2
40	Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival. Liver Transplantation, 2016, 22, 562-563.	1.3	1
41	Comparative analysis of estimated and measured maximal voluntary ventilation in patients with pulmonary hypertension. , 2016, , .		1
42	Mechanisms and consequences of exertional dyspnoea in combined pulmonary fibrosis and emphysema (CPFE). , 2019, , .		1
43	Refractory Arterial Hypotension in a Patient with COVID-19: Could the Hypothalamic-Pituitary-Adrenal Axis Be Involved? Case Report and Mini Review. Advances in Infectious Diseases, 2020, 10, 160-167.	0.0	1
44	SWITCHING TO RIOCIGUAT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION NOT AT TREATMENT GOAL WITH PHOSPHODIESTERASE TYPE-5 INHIBITORS: SUBGROUP ANALYSIS RESULTS OF THE REPLACE STUDY. Chest, 2020, 158, A2156-A2159.	0.4	0
45	Metabolic, cardiovascular and gas exchange abnormalities during activities of daily life in patients with idiopathic pulmonary arterial hypertension. , 2015, , .		0
46	Contrasting cardiovascular responses to exercise in mitochondrial myopathy and pulmonary arterial hypertension. , 2016, , .		0
47	Prognostic role of excessive exercise ventilation in non-operable patients with chronic thromboembolic pulmonary hypertension. , 2016, , .		0
48	Influence of inspiratory muscle weakness in exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH). , 2016, , .		0
49	The role of cardiopulmonary exercise testing in the diagnosis of psychogenic dyspnoea. , 2016, , .		0
50	Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). , 2016, , .		0
51	Short and long-term effects of pulmonary endarterectomy on ventilatory responses and exercise capacity of patients with chronic thromboembolic pulmonary hypertension. , 2017, , .		0
52	Clinical value of an abnormal increase of O2 pulse during early recovery from maximal exercise in patients with chronic thromboembolic pulmonary hypertension. , 2018, , .		0
53	Tomographic features associated with excessive ventilatory responses during exercise in chronic pulmonary thromboembolic hypertension. , 2018, , .		0
54	Incremental step test in patients with pulmonary hypertension. , 2018, , .		0